Effects of Niosomal Cisplatin and Combination of the Same with Theophylline and with Activated Macrophages in Murine B16F10 Melanoma Model

Abstract

The use of cisplatin is limited due to its certain toxic effects. In the present study niosomes of cisplatin by using span 60 and cholesterol were prepared and investigated for antimetastatic activity in experimental metastatic model of B16F10 melanoma. Theophylline and its combination effect with free cisplatin and niosomal cisplatin were also carried out in the same model. The effect of treatment with activated macrophages alone and in combination with cisplatin, theophylline and niosomal cisplatin was also observed. Treatment with niosomal cisplatin (1 mg/kg) and combination of the same with theophylline (15 mg/kg) showed significant reduction in the number of lung nodules as compared to untreated control as well as with free cisplatin (1 mg/kg). The treatment with activated macrophages (activated by using Muramyl dipeptide) significantly reduced the secondary growth of tumor in lung. Niosomal cisplatin showed a significant protection against weight loss and bone marrow toxicity as compared to free cisplatin. These results suggest that cisplatin encapsulated in niosomes has significant antimetastatic activity and reduced toxicities than that of free cisplatin. However theophylline failed to show antimetastatic effect alone or in combination with cisplatin or with activated macrophages.

Paclitaxel-loaded niosomes for intravenous administration: pharmacokineticsand tissue distribution in rats

“…There are several studies in which niosomes were evaluated as drug carrier systems for anticancer agents such as hydroxycamptothecin (HCPT), doxorubicin, methotrexate, 5-fluorouracil, cisplatin, and pentoxifylline (35)(36)(37)(38)(39)(40)(41)(42)(43)(44). The results obtained in the present study agree well with those of the previous studies.…”

In vitro and in vivo evaluation of Bola-surfactant containing niosomes for transdermal delivery

“…as immunological adjuvants (Jain et al, 2005), anti-cancer and anti-infective drug targeting agents (Balasubramaniam et al, 2002;Gude et al, 2002), carriers of anti-inflammatory drugs (Shahiwala and Misra, 2002) and as diagnostic imaging agents (Uchegbu and Vyas, 1998). In addition, niosomes are versatile carrier systems that can be administered through various routes.…”

Bioavailability of phytochemicals and its enhancement by drug delivery systems

“…Niosomal dispersion in an aqueous phase can be emulsified in a non-aqueous phase to regulate the delivery rate of drug and administer normal vesicle in an external non-aqueous phase. Niosomes have been proposed for a number of potential therapeutic applications, i.e., as immunological adjuvants [115], anticancer and anti-infective drug targeting agents [116,117], carriers of anti-inflammatory drugs [118] and as diagnostic imaging agents [114]. In addition, niosomes are versatile carrier systems and can be administered through various routes.…”